Both roads, in one place
Every other provider in this comparison sells compounded medication and nothing else. Found sells compounded semaglutide and tirzepatide on a flat program price. On a separate track, it sells the brand-name products — Wegovy, Ozempic, Zepbound, and Mounjaro — each carrying its own listed price. For a reader still deciding between a compounded preparation and an FDA-approved product, that is the difference between one intake and two.
The distinction being spanned here is not minor. A compounded preparation is prepared by a compounding pharmacy and has not been through the FDA approval process a brand-name GLP-1 has. They are different purchases at very different prices, and the gap between them is largely explaining itself. Found lets a reader weigh that trade-off without committing to a provider first and then finding the option they wanted is not available.
That is also why a reader should not compare Found's compounded figure against another provider's compounded figure and stop there. The brand-name route sits behind the same account, and for some readers that is the whole value of the platform.
One price for either compound, which is unusual
Found charges one flat program price that covers either compound, and it stays where it is while the dose climbs. Across this category, tirzepatide almost always costs more than semaglutide. A patient who starts on semaglutide and later moves to tirzepatide is not walking into a price increase. A patient who wants tirzepatide from the start is not paying the premium the rest of this set charges for it.
That is a genuinely reader-favorable structure, and the strongest single argument for Found on the compounded side. It also skews the comparison against other providers: Found looks better on tirzepatide and less so on semaglutide. Notice that before treating one figure as a verdict on the whole platform.
The twelve-month prepayment behind the headline
Found's lowest advertised price is gated behind prepaying a full year. Billing month to month lands substantially higher. That is not a rounding difference, it is a large step. The qualifier printed beside every figure carries the plan term for exactly that reason, because a Found figure quoted without its term describes a purchase most readers will not make.
A year prepaid is a real decision. It is a bet that treatment will suit you, that you will tolerate it, that you will want to continue, and that the provider will keep serving you well for twelve months. Some readers will take that bet happily and get the best compounded price in this comparison for it. Anyone less certain should price Found at its month-to-month rate and see whether it still wins. That is the number that applies to a first-time patient who wants an exit.
Found does publish a specific refund policy for its membership fee, which is more than most of this field commits to in writing. Read it against the prepaid term before deciding. Those two terms interact, and the interaction is the part that matters.
Where Found's own pages disagree
Found's own pricing pages are not consistent with each other on brand-name medication. One page presents a starting figure for a brand-name GLP-1 that is far below what the homepage carousel advertises for the same category. These are not two ways of saying the same thing. They are two different numbers on the same company's website, and the gap between them is wide.
The discrepancy is not resolved here. Resolving it would mean picking one of the provider's own numbers and presenting it as the truth, and there are no grounds for that. What matters is that the discrepancy exists. Treat a brand-name price as something to confirm directly with Found for your own situation, not something to carry away from a page.
The broader lesson is about reading Found's brand-name marketing carefully. The compounded side of the offering is priced clearly and consistently. The brand-name side is where the numbers move depending on which page you land on. Get a figure in writing for your own case before you count on it.
Disclosure: what Found shows and what it withholds
Found displays a LegitScript seal and states that it holds BBB accreditation. Both are published claims, not verdicts. A seal displayed on a page establishes that a seal is published. It does not establish who holds the underlying certificate, and one is not converted into the other here. If either credential is decisive for you, verify it at its source.
On the pharmacy question, Found goes no further than a licensing class: 503A. Which of those pharmacies fills a given order is never stated. A licensing category is a class, not an identity. It tells a reader what kind of pharmacy is involved without letting them look up the specific one. For a platform of this size, that is a disappointing place for the disclosure to stop, and at least one smaller provider in this comparison names more than one pharmacy outright.
Found's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $169/moper month, 12-month prepaid plan | August 2026source |
| Tirzepatide (compounded) | $169/moper month, 12-month prepaid plan | August 2026source |
| Semaglutide (brand) | $650/mostarting at, per month | August 2026source |
| Tirzepatide (brand) | $650/mostarting at, per month | August 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. None of the 16 providers reviewed here are paid partners today. See how this works.
See Found's current price →Good fit if
- Readers still deciding between a compounded preparation and a brand-name, FDA-approved GLP-1 who want both options behind one intake.
- Patients who want tirzepatide without paying the premium most providers in this comparison attach to it.
- Readers confident enough to prepay twelve months for the lowest rate, and who have read the membership refund policy alongside that commitment.
- People who want a published refund policy in writing rather than a verbal assurance at intake.
Look elsewhere if
- Anyone who wants to start month to month. Found's advertised rate needs a twelve-month prepayment, and the month-to-month rate is substantially higher.
- Readers relying on a brand-name figure they read on Found's site. Found's own pages disagree with each other about where brand-name pricing starts, by a wide margin — get a quote in writing.
- Patients who require the compounding pharmacy to be named. Found goes no further than the 503A licensing class, which is a category rather than an identity.
- Readers who treat a displayed seal or an accreditation claim as settled proof. They are published claims, and that is all they are.
How this review was verified
- Read Found's published pricing at its source URL and logged each figure — compounded and brand-name — with the date it was read.
- Attached the twelve-month prepaid plan term to the qualifier on the compounded figures, so the commitment cannot be separated from the number in a comparison table.
- Compared Found's own pricing pages against each other. They state different starting points for brand-name medication, and that difference is reported as a difference rather than settled by picking one of the company's figures.
- Described the displayed LegitScript seal and Found's stated BBB accreditation as published claims, and treated neither as establishing who holds the underlying credential.
- Checked how Found describes its compounding pharmacies. It names a licensing category, 503A, but not the pharmacy that fills a given order.